君實生物(01877.HK)與COHERUS許可與商業化協議終止
君實生物(01877.HK)公布,1月10日,收到Coherus關於終止重組人源化抗TIGIT單克隆抗體(項目代號:JS006)許可合作的通知,六個月後生效。屆時,Coherus不再享有JS006的許可權利,公司重新獲得開發、生產和商業化JS006的全部全球權利。終止不會影響終止不會影響收到的3,500萬美元執行費及Coherus承擔的研發費用等。
Coherus將繼續支持有關JS006單藥或與特瑞普利單抗聯合治療晚期腫瘤患者的I期臨床試驗中患者的相關工作,並逐步與公司過渡有關JS006的研究工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.